Chlamydia Screening strategy in the UKhow far have we come?

Similar documents
Lincolnshire JSNA: Chlamydia Screening

MEN AND CHLAMYDIA EXECUTIVE SUMMARY. ...up to one in ten sexually active young people now infected. PUTTING MEN TO THE TEST

APPENDIX A SERVICE SPECIFICATION

Service Specification

NEW GENERAL MEDICAL SERVICES CONTRACT SPECIFICATION FOR THE PROVISION OF AN ENHANCED SERVICE SERVICE SPECIFICATION CHLAMYDIA SCREENING

HC 963 SesSIon november Department of Health. Young people s sexual health: the National Chlamydia Screening Programme

CHLAMYDIA SCREENING ENHANCED SERVICE SERVICE SPECIFICATION. Page 1 of 12

STI & HIV screening in Primary Care. Dr Paddy Horner Consultant Senior Lecturer University of Bristol Annette Billing Public Health, Bristol Council

Appendix 1: Background data and details of analyses used in the study

Barnet Scrutiny Committee report 13 th October Barnet Sexual Health Strategy Dr Andrew Howe, Director of Public Health

Warrington Centre for Sexual Health WCSH Local Enhanced Service LES

RUclear? Summary 10/11

Telford & Wrekin Pharmacy LES Chlamydia Screening Page 1 of 16

Integrated Sexual Health and HIV Services. Dr Simon Edwards - Clinical Director Mark Maguire - Service Director

Briefing on new Sexual health and HIV services in Surrey

Blanche Heriot Unit Patient Information and Discussion Event Wednesday 9th August pm Room 3 Chertsey House St Peter s Hospital

Jill Davidson CEO SHine SA. On Line Chlamydia Initiative

Sexual health commissioning Frequently asked questions Published February Health, adult social care and ageing

Improving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities

Trends in STDs: US Perspective. Michael Towns, M.D. WW Vice President, Medical Affairs BD Diagnostic Systems

Sexual health in adolescents in the UK: What do the data show? Dr Gwenda Hughes and Dr Anthony Nardone Health Protection Services Colindale

Health Promotion Service Project Overview

Infection report. Sexually transmitted infections 1 and chlamydia screening in England, HIV-STIs. Recommendations:

Croydon Sexual Health Strategy

Infectious Diseases and Sexual Health in Southwark

Dual Diagnosis. Themed Review Report 2006/07 SHA Regional Reports East Midlands

The HIV Prevention England programme: what s next? Cary James May 2016

Family Planning Title X Chlamydia Screening Quality Improvement Project

The cost effectiveness of opportunistic chlamydia screening in England Adams E J, Turner K M, Edmunds W J

Dr Claudia Estcourt. Barts and the London School of Medicine and Dentistry THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014

Where do young men want to access STI screening? A stratified random probability sample survey of young men in Great Britain

Counting the Cost Economics of Sexually Transmitted Infections

Sexual Health Services (Emergency Hormonal Contraception, Chlamydia Screening, Condom Distribution & Pregnancy Testing) in Pharmacies.

Leicestershire Sexual Health Strategy

The National perspective Public Health England s vision, mission and priorities

The Future of Cervical Screening. Jenny Ross

Cost-effectiveness of abandoning microscopy of urethral smears for asymptomatic nonchlamydial non-gonococcal urethritis in men in the UK

Public health guideline Published: 28 February 2007 nice.org.uk/guidance/ph3

The Prime Minister s Challenge on Dementia Lorraine Jackson Deputy Director: Dementia Policy Department of Health 12 April 2016

STANDARD OPERATING PROCEDURE Chlamydia screening and treatment for year olds

STI in young people, the Swedish experience. Sexual Health Forum Brussels, 13 January Monica Ideström Senior Programme Officer, PhD

Statistical analysis of costs The results were mainly reported as deterministic data.

Strategic overview of sexual health procurement Haringey and London

Annual Epidemiological Report

Pneumococcal polysaccharide vaccine uptake in England, , prior to the introduction of a vaccination programme for older adults

STI control. Dr. Jane Morgan Hamilton Sexual Health Clinic

Health Scrutiny Panel 6 February 2014

A new model of HIV care management. Dr Simon Barton London UK

Improving Value in Chemotherapy

Ensuring effective commissioning of cancer services: A survey of GPs

Project Team. David Lewis Leela Barham

Cumbria Diabetes Dr Cathy Hay Clinical Director Cumbria Diabetes Cumbria Partnership NHS Foundation Trust

Outcomes from Local Cancer Campaigns Survey February 2016

Joint Strategic Needs Assessments (JSNA)

North Staffordshire Clinical Commissioning Group. Infertility and Assisted Reproduction Commissioning Policy and Eligibility Criteria

ASH/STCA Smoking Cessation in Secondary Care

British Academy of Audiology Heads of Service Day

Conception rate. Merthyr Tydfil North East. Wrexham Rhondda, Cynon, Taf Yorkshire and the Humber. Blaenau Gwent Neath Port Talbot

The new PH landscape Opportunities for collaboration

PATIENT GROUP DIRECTION

HIV/AIDS, STI, hepatitis

ICPD +10: Sexual and reproductive health and rights in the UK in 2004

4. Chlamydia. Treatment: Treating infected patients prevents further transmission to sex partners. In addition, treatment of chlamydia in pregnant

Networking for success: A burning platform in Berkshire West

Terrence Higgins Trust Norfolk Chlamydia Screening Programme (NorfolkCSP)

GUMCAD STI Surveillance System (DCB0139) Implementation Guidance

Harm reduction among drug users in Spain

Gateway reference : 13683

National HIV self-sampling service

Preparing for the Homelessness Reduction Act 2017

T he prevalence of genital chlamydial infection is 3 10% in

Diabetes Network

HIV testing in England and the NICE Quality Standards

Dumfries and Galloway Alcohol and Drug Partnership. Strategy

ROLE SPECIFICATION FOR MACMILLAN GPs

The next steps

Ending HIV and Australia s success story in PrEP implementation Dr Heather-Marie Schmidt

Large increase in opportunistic testing for chlamydia during a pilot project in a primary health organisation

Quality care. Everywhere? An audit of prostate cancer services in the UK

Opportunistic and systematic screening for chlamydia:

Needle and Syringe Programs - 17 October 2013

Surve ill an ce re p o r t s

Evaluation of the Health and Social Care Professionals Programme Interim report. Prostate Cancer UK

Hospital Authority. Pilot Scheme on Dementia Community Support Services for the Elderly

Chloe Robinson, Anthony Nardone, Catherine Mercer, Anne M. Johnson. Summary

Solihull Safeguarding Adults Board & Sub-committees

HIV in London: A Complexity Challenge

Viral Load Suppression/Any HIV Care 84%

Public Health Observatories: An introduction to the London Health Observatory in England and recent developments in Alberta. Learning objectives

Trends in Reportable Sexually Transmitted Diseases in the United States, 2007

METRO ASSOCIATES WELCOME PACK

Subject: NHS Screening and Immunisation Programmes T

Has the UK had a double epidemic?

Report to the Merton Clinical Commissioning Group Governing Body

NHS ENGLAND BOARD PAPER

An Illustrative Communication Strategy for Female Condoms: Step 5 (Determine Activities and Interventions) 1

Young People. & Brexit. New Age for. democracy. Our. Living. Minds. Wage for Everyone. Matter. Save our. Youth. Teach. Services. First Aid.

National Diabetes Audit

Mike Jones. Alcohol Programme Manager GM Public Health Network NHS Greater Manchester

Transcription:

Chlamydia Screening strategy in the UKhow far have we come? Dr Janette Clarke Chair, National Chlamydia Screening Advisory Group Department of Health England Jan.clarke@leedsth.nhs.uk 13/01/2010

National Chlamydia Screening Programme operates in England only

Strategies influencing Improving young people s sexual health services Community based service developments User choice within integrated treatment services Target driven investment by local health economies Enhancing quality and patient safety Sophisticated social marketing

Majority of all chlamydia diagnosed is found in 16-24 year olds and has no warning symptoms Rate per 100,000 population 1400 1200 1000 800 600 400 200 Men <16 16-19 20-24 25-34 35-44 45+ 20-24 years 1400 1200 1000 800 600 400 200 Women 16-19 years 20-24 years 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Rates of genital chlamydial infection by sex and age group: 1995-2004 Data source: KC60 and STISS/ISD(D)5 returns from GUM clinics, United Kingdom

Costs and consequences Genital Chlamydia PID 10-40% of untreated infections Infertility (20% linked to C. trachomatis) Ectopic Pregnancy (47% linked to C. trachomatis) Costs to NHS c. 120 million per year (excluding IVF)

Non-invasive testing

Texting and treatment

Goals of NCSP Prevent and control chlamydia through early detection and treatment of asymptomatic infection Reduce transmission to sexual partners Prevent consequences of untreated infection

1999-2000 Pilots supported screening strategy n= 17,000 High acceptance: 76-84% of women accepted screening when offered High coverage: Effective screening rate was 46-59% within 1 year High prevalence: 10% among 16-24 yr old women attending community contraception services

2001 Sexual Health Strategy supports chlamydia screening Develop community services Contraception HIV testing STIs 2001-3 phased pilots, men included Full rollout by 2008

A new young people s sexual health service National level advice to DH and HPA on progress-ncsag HPA central and regional teams facilitate, monitor, manage data 152 PCTs commission within a locality 92 areas Set up local steering group Local venues recruited Fund office

Opportunistic screening offer to all sexually active young people under 25 years old Healthcare settings Contraception clinics Young peoples services General practices Pharmacies TOP services Gynaecology services Non healthcare settings Youth clubs YOI and prisons Military bases Schools and colleges Outreach events pee in a pot days, health fairs Postal kits

Expanding awareness of STIs and Chlamydia in young people

Partner management essential element of programme Prevent re-infection, transmission Any age, free treatment Expert partner notification as needed Coordinated followup through local office

Community based service development 2006-8 Huge expansion of screening, STI testing and treatment services in community settings. Nurses and community pharmacists dispense without medical prescription National Support team (DH) disseminates good practice.

Policies and politics Community rather than hospital based Encouraging alternate providers Private pharmacies charities

Enhancing skills of community services expands patient choice CSO-centred model Integrated model CSO manages positives and partners Management in local (community) clinical services

Operating framework targets Targets for each PCT Screening percentages of 16-24 year olds within NCSP and in community 17% 2008/9 25% 2009/10 35% 2010/11 + GU Medicine =50%

The challenge 6.5 million young people aged 15-24yrs in England 80% sexually active = 5.3 million target population Screen annually to bring down prevalence 50% coverage, 0.2 partners per case treated Prevalence 8% 6% 4% 2% 0% 16-19 yr 20-24 yr 25-29 yr 30-34 yr 35-39 yr 40-44 yr -1 0 1 2 3 4 5 6 7 8 9 10 Time (years) Source: Turner, Adams, LaMontagne et al STI 2006

Latest statistics 11,891 NCSP sites active from April 2009. In 2008/9: 1,064,167 tests outside GU Medicine 759,027 screens in NCSP registered venues Diagnosed 57,704 young people with chlamydia 88% documented as treated 0.4 partners per case treated

Chlamydia testing coverage among 15-24 year olds: England 2008/9 30.00 25.00 20.00 15.00 10.00 24% 24% 25% 26% 27% 28% 24% 20% 20% 21% 21% GUM Non NCSP non GUM NCSP 5.00 0.00 South East Coast West Midlands East Midlands South Central East of England South West North West Yorkshire and Humber North East London ENGLAND Non GUM data as of 22.05.09. GUM data based on estimates from KC60 and GUMCAD. Percent of 15-24 year olds tested

England Chlamydia testing volumes: April 2003 March 2009 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 600,000 500,000 Nationally 1,768,747 tests to date 400,000 300,000 200,000 Nationally 1,064,167 tests in 2008/9 Number of tests 100,000 0 Apr-Jun 03 Oct-Dec 03 Apr-Jun 04 Oct-Dec 04 Apr-Jun 05 Oct-Dec 05 Apr-Jun 06 Oct-Dec 06 Apr-Jun 07 Oct-Dec 07 Apr-Jun 08 Oct-Dec 08 Apr-Jun 09 Oct-Dec 09 Data as of 22.05.09. Based on those aged 15-24 years. VSI criteria

Where are young people being tested? April 08 March 09 Coverage 23.6% Coverage 8.1% Data as of 22.05.09. Based on those aged 15-24 years. VSI criteria

Meeting the target is possible by increased coverage Type of core service Number of services engaged by the NCSP Number of tests/service/ week Total number of tests Contraception 3027 (60%) 5 726,480 GP 6059 (60%) 5 1,454,160 Pharmacy 2478 (20%) 5 594,720 ToP 129 (N/A) 5 30,960 TOTAL 2,806,320 2.8M = approximately 42%* coverage within NCSP core services Projected total coverage = approximately 52%^* * Based on mid-2009 ONS projections. ^ Total coverage includes NCSP and non NCSP non GUM data. Note: Total number of sites was obtained from NHS Choices, NHS ODS data (Organisation Data Services) and Business universe data

The future of in England is under intense scrutiny Benefits not just in screening volume Implementing the programme has involved many stakeholders The programme competes for resources in a complex health community can be fully integrated into local service networks

Acknowledgements Department of Health Andrea Duncan, Teresa Battison, Bill Jobson, Jane Mezzone, Steve Penfold National Chlamydia Screening Advisory Group Paddy Horner, Gill Bell, Cathy Ison, Leslie Bacon, Simone Reuter, Hong Tan, Sue Skidmore, Noel Gill, Ian Simms, Richard Ma, Mary Macintosh, Director and the NCSP central operational group at the HPA: Paula Baraitser, Marie Kernec, Jennie Uffindell, Johanna Rhia, Ali Talebi, Carla Maurici www.chlamydiascreening.nhs.uk

Strategies in Chlamydia screening Opportunistic screening Community based provision Local focus but national framework Social marketing Integration with sexual health services

This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.